HAO Haoxi Health Technology Ltd

Overview and Growth

In fiscal 2026, Haoxi Health Technology Ltd recorded $54.83M of revenue, net loss of $9.54M, and an operating cash outflow of $2.57M. The $54.83M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Revenue was 67.1% above fiscal 2025 revenue of $32.80M, marking a year-over-year increase. On a per-share basis, diluted EPS was -$386.40, which connects the reported earnings outcome with the company’s diluted share count. Diluted EPS decreased by 111.4% from $3385.53 in fiscal 2025, showing how the earnings change reached shareholders on a per-share basis. Diluted shares averaged 24.68K; this is the reported share base over which the company’s diluted per-share earnings were spread. The company employed $21.57M of total assets, the balance-sheet base supporting its current operating and cash-flow results. The revenue-to-assets relationship was 2.54x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Gross profit was $629.09K, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross profit represented 1.1% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $9.66M, reflecting costs that exceeded gross profit. The operating loss equaled 17.6% of revenue, showing the scale of the operating deficit relative to sales. The company ended the period with a net loss of $9.54M, extending the operating result through all remaining items. Net margin was -17.4%, reflecting a loss equal to 17.4% of reported revenue. The company reported negative EBITDA of $9.36M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. The pretax result was a loss of $9.50M, establishing the deficit before tax effects. Pretax margin was -17.3%, reflecting a pre-tax loss equal to 17.3% of revenue. The reported income-tax provision was $36.61K, the amount recognized between pretax income and the final net-income result. The net loss equaled 53.4% of period-end equity, showing the deficit relative to book capital. The loss-to-assets relationship was 44.2%, placing the bottom-line deficit against the company’s resource base. A $9.54M net loss replaced fiscal 2025 net income of $3.88M.

Liquidity and Capital Structure

The company held $21.57M of assets against $3.71M of liabilities and $17.86M of equity, revealing how the asset base was financed. Current assets were $16.81M against $3.71M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered current liabilities by 4.53x, leaving a positive buffer for near-term obligations. The company held $10.93M in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 294.6% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The equity-to-assets relationship was 82.8%, placing book capital against the total resource base. Liabilities represented 17.2% of total assets, quantifying the liability-funded share of the company’s resource base. The cash-to-assets relationship was 50.7%, comparing reported cash and equivalents with the full positive asset balance. Total assets were 0.1% lower than fiscal 2025 assets of $21.60M, measuring the company’s own balance-sheet change. Reported equity changed 2.8% from $17.38M in fiscal 2025, placing the current capital base higher year over year. Cash and equivalents were 26.9% higher than fiscal 2025 cash of $8.62M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $2.57M, showing that operations absorbed cash during the period. The operating cash outflow narrowed to $2.57M from $3.36M in fiscal 2025.

Based on the annual report for the fiscal year ending Jun 30, 2026. Analysis generated Oct 21, 2026.